Trial Profile
Open Label Phase I Trial of intramyocardial AMG0001-01 administration in chronic heart failure patients with ischemic cardiomyopathy
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 29 Jul 2016
Price :
$35
*
At a glance
- Drugs Beperminogene perplasmid (Primary)
- Indications Ischaemic heart disorders
- Focus Adverse reactions
- 27 Jul 2016 Status changed from recruiting to discontinued.
- 22 Oct 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan
- 24 Jul 2014 Planned initiation date changed from 1 Jul 2014 to 1 Oct 2014 as reported by University Hospital Medical Information Network - Japan